Time on boards
- Boards served
- 3
- Current seats
- 3
- Board service
- 10 years
- Director since
- 2023
10 years of board service in total across 3 boards, counting each seat separately. Longest: F5 Inc., 3 years.
F5 Inc.
Director
Denali Therapeutics Inc.
Director
Palladyne AI Corp.
Director
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Denali Therapeutics Inc. June 3, 202587.9%
-
F5 Inc. March 13, 202596.8%
-
F5 Inc. March 14, 202494.5%
-
F5 Inc. March 9, 202388.7%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 3, 2026 | Denali Therapeutics Inc. | Grant or award | +6,408 | — | — |
| Jun 3, 2025 | Denali Therapeutics Inc. | Grant or award | +6,037 | — | — |
| Mar 12, 2025 | F5 Inc. | Option exercise | +1,309 | — | — |
| Sep 5, 2024 | F5 Inc. | Gift | −1,000 | — | — |
| May 31, 2024 | Denali Therapeutics Inc. | Grant or award | +5,967 | — | — |
| Mar 13, 2024 | F5 Inc. | Option exercise | +1,770 | — | — |
| Sep 5, 2023 | F5 Inc. | Gift | −1,200 | — | — |
| Jun 14, 2023 | Palladyne AI Corp. | Grant or award | +195,059 | — | — |
| Jun 1, 2023 | Denali Therapeutics Inc. | Grant or award | +4,216 | — | — |
| Mar 8, 2023 | F5 Inc. | Option exercise | +1,272 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.